|
|
DHEA vaccine adjuvant |
|
Vaxjo ID |
93 |
|
Vaccine Adjuvant Name |
DHEA vaccine adjuvant |
|
Alternative Names |
Dehydroepiandrosterone; 5-androsten-3β-ol-17-one; dehydroisoandrosterone; androstenolone; prasterone; transdehydroandrosterone; DHA |
|
Adjuvant VO ID |
VO_0001340
|
|
Stage of Development |
Clinical Trial |
|
Molecular Weight |
288.4 |
|
Appearance |
White, colorless powder or crystals. |
|
Storage |
DHEA is relatively stable, however, its double bond is susceptible to both addition and oxidation reactions. Long term storage under dry inert gas at or below -20° C (Vogel and Powell, 1995). |
|
Function |
DHEA can be directly incorporated into vaccine formulations (2-10 µg/ vaccination in mice, 100 µg/ vaccination in dogs) and will enhance antibody formation (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
